Journal article

Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT

Bill Deakin, John Suckling, Paola Dazzan, Eileen Joyce, Stephen M Lawrie, Rachel Upthegrove, Nusrat Husain, Imran B Chaudhry, Graham Dunn, Peter B Jones, Danuta Lisiecka-Ford, Shôn Lewis, Thomas RE Barnes, Steven CR Williams, Carmine M Pariante, Emma Knox, Richard J Drake, Richard Smallman, Nicholas M Barnes

Efficacy and Mechanism Evaluation | National Institute for Health Research | Published : 2019


Background In a previous trial we reported that the neuroprotective, anti-inflammatory antibiotic minocycline lessened the negative symptoms of schizophrenia compared with placebo over 1 year. The BeneMin study aimed to replicate this benefit and to determine whether or not there was associated preservation of grey matter, reduction in circulating inflammatory cytokines and enhancement of cognition. Objectives To determine the efficacy of minocycline on the negative symptoms of schizophrenia and the mechanistic role of neuroprotective, anti-inflammatory and cognitive enhancing actions. ..

View full abstract


Citation metrics